![]() However, several pre-clinical studies have demonstrated the regenerative potential of Mesenchymal Stem Cells (MSCs) in the establishment of spinal cord repair protocols ( 7– 9). This massive biochemical cascade contributes to a wide range of pathological events that serve as a substrate to secondary degeneration involving neurotoxicity, vascular dysfunction, glial scarring, neuroinflammation, apoptosis and demyelination ( 2– 6).ĭespite substantial advancements in our understanding of the complex pathophysiology of SCI, completely restorative treatments and neuroprotective resources for SCI management are limited. The instantaneous primary injury event involves mechanical trauma to the spinal cord and its components that sets into motion a local and systemic response with both acute and chronic effects. The pathophysiology of SCI involves an intense inflammatory response, with elevated levels of cytokines and pro-inflammatory mediators. Individuals who sustain SCI suffer from varying degrees of impairments that adversely affect their quality-of-life. SCI is a debilitating disease affecting more than 1 million people in the United States alone, with approximately 17,000 new cases occurring every year ( 1). Spinal cord injury (SCI) is a chronic neurological disorder caused by damage to the spinal cord leading to disruption of neural circuitry that may cause temporary or permanent, motor, sensory or autonomic dysfunctions. Further research is needed to evaluate the results of this study. Multiple intravenous infusions of autologous HB-adMSCs for treatment of SCI demonstrated significant enhancements in the patient's neurological function with improved quality-of-life. ![]() No safety concerns were presented, and no serious adverse events were reported during the entire course of treatment. Additionally, electromyography/nerve conduction velocity (EMG/NCV) studies showed improvements in the patient's motor and sensory function. Thirty-four (34) recurrent infusions each with 200 million cells were administered, over a period of ∼2.5 years, which resulted in significant improvements in his quality-of-life as demonstrated by substantial improvements in SCIM-III (Spinal Cord Independence Measure III) scores. ![]() On September 12, 2019, an Individual Expanded Access Protocol was approved for administration of multiple infusions of autologous, adipose-derived MSCs (adMSCs) for the treatment of this quadriplegic incomplete C5-6 SCI patient. He was diagnosed with C5–C6 Grade 2 anterolisthesis with flexion teardrop fracture of the anterior C6 with jumped facet on the right and perched facet on the left at C5–C6 with spinal canal stenosis. ![]() Here, we present a case of a 41-year-old quadriplegic male individual who experienced a traumatic C-5 incomplete SCI, after slipping off a boat in Florida Keys on August 4, 2017. Recent advancements in stem cell research have elucidated the therapeutic potential of mesenchymal stem cells (MSCs) for the treatment of patients with SCI. Spinal cord injury (SCI) is a debilitating disease with clinical manifestations ranging from incomplete neurological deficits affecting sensory and motor functions to complete paralysis. ![]() 2Cell Production, Hope Biosciences, Sugar Land, TX, United States.1Clinical Research, Hope Biosciences Research Foundation, Sugar Land, TX, United States.Ridhima Vij 1* † Hosu Kim 2 Hyeonggeun Park 2 Thanh Cheng 1 Djamchid Lotfi 1 Donna Chang 1,2 ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |